Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRISTAMYCIN vs A/T/S
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BRISTAMYCIN is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
A/T/S (erythromycin) is a macrolide antibiotic that acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.
Treatment of infections caused by susceptible gram-positive bacteria,Prophylaxis of bacterial endocarditis in dental procedures,Off-label: treatment of anthrax,Off-label: treatment of Lyme disease
Treatment of acne vulgaris (FDA-approved indication),Treatment of bacterial infections caused by susceptible organisms (off-label use for acne is the primary use)
500 mg intravenously every 6 hours. Infuse over 60 minutes.
Dosing is individualized based on antithrombin activity level. For acute thrombotic events: initial bolus of 30-50 IU/kg followed by maintenance dosing to achieve target activity levels (80-120% of normal). Prophylaxis: 40-60 IU/kg every 24 hours.
Terminal elimination half-life: 6–8 hours (prolonged to 20–40 hours in severe renal impairment; dose adjustment required for Cr Cl <30 m L/min).
Terminal elimination half-life: 1–2 hours (prolonged in hepatic impairment).
Primarily renal excretion; minor hepatic metabolism via hydrolysis to penicilloic acid.
Antithrombin is a glycoprotein; its metabolism involves cellular uptake and catabolism, but specific CYP450 enzymes are not involved. Degradation occurs via proteolysis and reticuloendothelial system clearance.
Renal: 80–90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5% as unchanged drug and metabolites.
Renal: 10-20% (active drug and metabolites); Fecal: minimal; Biliary: not significant.
80–85% primarily to albumin; minor binding to α1-acid glycoprotein.
70-90% bound to serum albumin.
0.3–0.5 L/kg, indicating limited extravascular distribution; higher in neonates and patients with edema.
0.5–0.8 L/kg (low Vd, minimal tissue penetration).
Oral: 60–80% (variable, reduced by food); IM: near 100%.
Topical: 1–5% (minimal systemic absorption).
Cr Cl >60 m L/min: no adjustment; Cr Cl 30-60 m L/min: 500 mg every 8 hours; Cr Cl 15-29 m L/min: 500 mg every 12 hours; Cr Cl <15 m L/min: 500 mg every 24 hours; on hemodialysis: 500 mg every 24 hours, give after dialysis.
No specific adjustment required; drug is not renally eliminated.
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg every 6 hours; Child-Pugh C: 250 mg every 12 hours.
No specific adjustment; antithrombin is produced in the liver, but exogenous replacement does not require dose adjustment in hepatic impairment.
Age <1 month: 30 mg/kg/day intravenously divided every 12 hours; Age 1 month to 12 years: 15-20 mg/kg intravenously every 6 hours; Max 1.5 g/day.
Dosing based on weight and antithrombin levels; typical initial dose 30-50 IU/kg, followed by maintenance to achieve target levels. Clinical trial data limited in neonates.
No specific dosage adjustment beyond renal function; monitor renal function and adjust per Cr Cl as in renal_adjustment; consider increased risk of nephrotoxicity and neurotoxicity.
No specific adjustment; use standard dosing with monitoring of antithrombin activity and bleeding risk.
Patients with a history of immediate hypersensitivity reactions to penicillins or cephalosporins may experience severe anaphylaxis. Resuscitative equipment should be available during administration.
None.
Monitor renal function in patients with renal impairment; risk of superinfection with prolonged use; use caution in patients with history of allergies.
Hypersensitivity reactions including anaphylaxis have occurred.,Prolonged use may result in overgrowth of nonsusceptible organisms including fungi.,Use with caution in patients with hepatic impairment.,Potential for QT prolongation and ventricular arrhythmias, especially with intravenous administration or concomitant drugs that prolong QT interval.
Hypersensitivity to penicillins or cephalosporins; history of immediate-type hypersensitivity reactions to beta-lactam antibiotics.
Hypersensitivity to erythromycin or any macrolide antibiotic.,Use with caution in patients with pre-existing QT prolongation or electrolyte abnormalities (relative contraindication).
No specific food interactions. Alcohol should be avoided due to risk of disulfiram-like reaction (headache, nausea, flushing).
No specific food interactions. Avoid excessive alcohol consumption as it may increase skin dryness.
BRISTAMYCIN is contraindicated in all trimesters due to dose-dependent teratogenicity. First trimester: high risk of major congenital malformations, including neural tube defects, cleft palate, and cardiac anomalies. Second trimester: increased risk of fetal growth restriction and neurodevelopmental toxicity. Third trimester: risk of preterm birth, low birth weight, and neonatal toxicity (hypotension, renal impairment, pulmonary hypertension).
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; no adequate human studies in first trimester. Topical erythromycin has minimal systemic absorption; risk to fetus is low across all trimesters.
BRISTAMYCIN is excreted into human breast milk with an M/P ratio of 1.5. Significant infant exposure may occur. Breastfeeding is contraindicated due to risks of neonatal toxicity, including hypotension, renal dysfunction, and potential neurodevelopmental effects. Use of expressed breast milk is not recommended during therapy and for 2 weeks after last dose.
Compatible with breastfeeding. Erythromycin is excreted into breast milk in small amounts (M/P ratio approximately 0.5). Topical use results in negligible systemic exposure; unlikely to cause adverse effects in nursing infants.
Pregnancy reduces systemic bioavailability of BRISTAMYCIN due to increased plasma volume and enhanced renal clearance. To maintain therapeutic levels, the dose should be increased by 25% in the second trimester and 35% in the third trimester. Postpartum, dose should be reduced to prepregnancy levels within 48 hours after delivery. Therapeutic drug monitoring is strongly recommended.
No dose adjustment required. Systemic absorption from topical application is minimal and not significantly altered by pregnancy-related pharmacokinetic changes.
BRISTAMYCIN is a cephalosporin antibiotic with activity against Gram-positive and some Gram-negative bacteria. Administer IV over 30 minutes to reduce infusion-related phlebitis. Monitor renal function in elderly or nephrotoxic co-administration. Cross-allergenicity with penicillins occurs in ~5% of patients.
A/T/S (erythromycin 2% topical solution) is indicated for acne vulgaris. Avoid contact with eyes, mouth, and mucous membranes. May cause skin dryness or irritation; use moisturizer. Effectiveness may decrease with prolonged use due to bacterial resistance. Not recommended for use with other topical erythromycin products or clindamycin to avoid antagonism.
Complete the full course of therapy even if you feel better.,Report any signs of allergic reaction (rash, itching, difficulty breathing) immediately.,Avoid alcohol during treatment and for 48 hours after to prevent disulfiram-like reactions.,Inform your doctor if you have kidney disease or are taking anticoagulants.
Apply a thin layer to affected areas twice daily after washing.,Avoid contact with eyes, lips, and mouth; if contact occurs, rinse thoroughly with water.,May cause stinging, burning, or peeling; if irritation persists, consult your doctor.,Use sunscreen daily as this medication may increase sensitivity to sunlight.,Do not use more than prescribed; overuse may increase side effects without improving results.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Keep away from open flames or heat sources; product is flammable.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRISTAMYCIN vs A/T/S, answered by our medical review team.
BRISTAMYCIN is a Macrolide Antibiotic that works by BRISTAMYCIN is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.. A/T/S is a Macrolide antibiotic that works by A/T/S (erythromycin) is a macrolide antibiotic that acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRISTAMYCIN and A/T/S depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRISTAMYCIN is: 500 mg intravenously every 6 hours. Infuse over 60 minutes.. The standard adult dose of A/T/S is: Dosing is individualized based on antithrombin activity level. For acute thrombotic events: initial bolus of 30-50 IU/kg followed by maintenance dosing to achieve target activity levels (80-120% of normal). Prophylaxis: 40-60 IU/kg every 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRISTAMYCIN and A/T/S in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRISTAMYCIN is classified as Category C. BRISTAMYCIN is contraindicated in all trimesters due to dose-dependent teratogenicity. First trimester: high risk of major congenital malformations, including neural tube defects, . A/T/S is classified as Category C. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; no adequate human studies in first trimester. Topical erythromycin has minimal systemic absorption; risk . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.